Emerging drugs for diabetic macular edema

Expert Opinion on Emerging Drugs

Volumn 19, Issue 3, 2014, Pages 397-405

  Schwartz, Stephen G ^b   Flynn Jr , Harry W ^b   Scott, Ingrid U ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Aflibercept; Bevacizumab; Dexamethasone; Diabetic macular edema; Fluocinolone acetonide; Randomized clinical trial; Ranibizumab; Triamcinolone acetonide; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; GLUCOCORTICOID; VASCULOTROPIN A;

ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DIABETIC RETINOPATHY; DRUG APPROVAL; DRUG DESIGN; HUMAN; MACULAR EDEMA; PATHOPHYSIOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; DIABETIC RETINOPATHY; DRUG APPROVAL; DRUG DESIGN; GLUCOCORTICOIDS; HUMANS; MACULAR EDEMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84906806277     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1517/14728214.2014.938048     Document Type: Review

References (63)

1. Klein R, Knudtson MD, Lee KE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009;116:497-503
2. Rodriguez-Fontal M, Kerrison JB, Alfaro DV, Jablon EP. Metabolic control and diabetic retinopathy. Curr Diabetes Rev 2009;5:3-7
3. Sivaprasad S, Gupta B, Crosby-Nwaobi R, Evans J. Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective. Surv Ophthalmol 2012;57:347-70
4. Ehrlich R, Harris A, Ciulla TA, et al. Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol (Copenh) 2010;88:279-91
5. Morigi M, Angioletti S, Imberti B, et al. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J Clin Invest 1998;101:1905-15
6. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-25
7. Shams N, Ianchulev T. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol Clin North Am 2006;19:335-44
8. Miyamoto N, de Kozak Y, Jeanny JC, et al. Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy. Diabetologia 2007;50:461-70
9. Cai W, Rook SL, Jiang ZY, et al. Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth. Invest Ophthalmol Vis Sci 2000;41:1885-93
10. Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep 2012;12:346-54
11. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556-64
12. Romero-Aroca P, Baget-Bernaldiz M, Fernandez-Ballart J, et al. Ten-year incidence of diabetic retinopathy and macular edema: risk factors in a sample of people with type 1 diabetes. Diabetes Res Clin Pract 2011;94:126-32
13. Klein R, Klein BEK, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XV: the long term incidence of macular edema. Ophthalmology 1995;102:7-16
14. Minassian DC, Owens DR, Reidy A. Prevalence of diabetic macular oedema and related health and social care resource use in England. Br J Ophthalmol 2012;96:346-9
15. Bressler NM, Varma R, Doan QV, et al. Underuse of the health care system by persons with diabetes mellitus and diabetic macular edema in the United States. JAMA Ophthalmol 2014;132:168-73
16. Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
17. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33. Lancet 1998;352:837-53
18. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-806
19. Javey G, Schwartz SG, Flynn HW Jr. Emerging pharmacotherapies for diabetic macular edema. Exp Diabetes Res 2012;2012:548732
20. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets 2005;6:511-24
21. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789-801
22. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-7
23. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study). 12-month data: report 2. Ophthalmology 2010;117:1078-86
24. Schmidt-Erfuth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014;121:193-201
25. Korobelnik JF, Holz FG, Roider J, et al. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology 2014;121:202-8
26. Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012;119:1658-65
27. Regeneron and Bayer report positive one-year results from two phase 3 trials of EYLEA (aflibercept) injection for the treatment of diabetic macular edema. Available from: http://investor.regeneron.com/releasedetail.cfm? releaseid=782911 [Last accessed 11 April 2014]
28. Nauck M, Roth M, Tamm M, et al. Induction of vascular endothelial growth factor by platelet-activating growth factor and platelet-derived growth factor is downregulated by corticosteroids. Am J Respir Cell Mol Biol 1997;16:398-406
29. Ayalasomayajula SP, Ashton P, Kompella UB, et al. Fluocinolone inhibits VEGF expression via glucocorticoid receptor in human retinal pigment epithelial (ARPE-19) cells and TNF-alpha-induced angiogenesis in chick chorioallantoic membrane (CAM). J Ocul Pharmacol Ther 2009;25:97-103
30. Edelman JL. Differentiating intraocular glucocorticoids. Ophthalmologica 2010;224(Suppl 1):225-30
31. Beck RW, Edwards AR, Aiello LP, et al. Three-year follow-up of a randomized trail comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127:245-51
32. Schwartz SG, Flynn HW Jr, Beer P. Intravitreal triamcinolone acetonide use in diabetic macular edema: illustrative cases. Ophthalmic Surg Lasers Imaging 2010;1-6
33. Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011;118:2453-60
34. Lowder C, Belfort R Jr, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011;129:545-53
35. Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010;128:289-96
36. Boyer DS, Faber D, Gupta S, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011;31:915-23
37. Schwartz SG, Flynn HW Jr. Fluocinolone acetonide implantable device for diabetic retinopathy. Curr Pharm Biotechnol 2011;12:347-51
38. Pearson PA, Comstock TL, Ip M, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011;118:1580-7
39. Schwartz SG, Flynn HW Jr. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor injections. Curr Ophthalmol Rep 2014;2(1):1-5
40. Milder E, Vander J, Shah C, Garg S. Changes in antibiotic resistance patterns of conjunctival flora due to repeated use of topical antibiotics after intravitreal injection. Ophthalmology 2012;119:1420-4
41. Yin VT, Weisbrod DJ, Eng KT, et al. Antibiotic resistance of ocular surface flora with repeated use of a topical antibiotic after intravitreal injection. JAMA Ophthalmol 2013;131:456-61
42. Schwartz SG, Flynn HW Jr, Scott IU. Intravitreal corticosteroids in the management of diabetic macular edema. Curr Ophthalmol Rep 2013;1(3): doi; 10.1007/s40135-013-0015-3
43. American Society of Retina Specialists. Preferences and Trends Survey. 2012. Available from: http://www.asrs.org/content/documents/- 2012asrspatsurveyresults.pdf [Last accessed 11 April 2014]
44. Mitchell P, Wong TY; Diabetic Macular Edema Treatment Guideline Working Group. Management paradigms for diabetic macular edema. Am J Ophthalmol 2014;157:505-13
45. Pershing S, Enns EA, Matesic B, et al. Cost-effectiveness of diabetic macular edema. Ann Intern Med 2014;160:18-29
46. Schwartz SG, Scott IU, Flynn HW Jr, Stewart MW. Drug delivery techniques for treating age-related macular degeneration. Expert Opin Drug Deliv 2014;11:61-8
47. Kompella UB, Kadam RS, Lee VH. Recent advances in ophthalmic drug delivery. Ther Deliv 2010;1:435-56
48. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-47
49. Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:1522.e1-1522.e14
50. Krishnadev N, Forooghian F, Cukras C, et al. Subconjunctival sirolimus in the treatment of diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2011;249:1627-33
51. Dugel PU, Blumenkranz MS, Haller JA, et al. A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema. Ophthalmology 2012;119:124-31
52. Bonini-Filho MA, Jorge R, Barbosa JC, et al. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial. Invest Ophthalmol Vis Sci 2005;46:3845-9
53. Diabetic Retinopathy Clinical Research Network. Chew E, Trauber S, et al. Randomized trial of peribulbar triamcinolone acetonide with and without photocoagulation for mild diabetic macular edema: a pilot study. Ophthalmology 2007;114:1190-6
54. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for age-related macular degeneration. N Engl J Med 2004;351:2805-16
55. Sultan MB, Zhou D, Loftus J, et al. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011;118:1107-18
56. Stalmans P, Benz MS, Gandorfer A, et al. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 2012;367:606-15
57. de Smet MD, Castilla M. Ocriplasmin for diabetic retinopathy. Expert Opin Biol Ther 2013;13:1741-7
58. Dmowski WP. Danazol: a synthetic steroid with diverse biologic effects. J Reprod Med 1990;35(Suppl):69-74
59. Thomas GW, Rael LT, Shimonkevitz R, et al. Effects of danazol on endothelial cell function and angiogenesis. Fertil Steril 2007;88(4 Suppl):1065-70
60. Bar-Or D, Thomas G, Salottolo K, et al. Oral danazol for DME. Retina Today 2012;68-70
61. Lisak RP, Nedelkoska L, Bejamins JA. Effects of dextromethorphan on glial cell function: proliferation, maturation, and protection from cytotoxic molecules. Glia 2014;62:751-62
62. Goel S, Gupta N, Walcott BP, et al. Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. J Natl Cancer Inst 2013;105:1188-201
63. Lu P, Li L, Liu G, et al. Opposite roles of CCR2 and CX3CR1 macrophages in alkali-induced corneal neovascularization. Cornea 2009;28:562-9